Aclaris Therapeutics, Inc. (LON:0H8T)
2.240
-0.122 (-5.16%)
Feb 20, 2025, 2:54 PM BST
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $4.35M USD in the quarter ending September 30, 2024, a decrease of -53.18%. This brings the company's revenue in the last twelve months to $27.08M, up 26.35% year-over-year. In the year 2023, Aclaris Therapeutics had annual revenue of $31.25M with 5.03% growth.
Revenue (ttm)
$27.08M
Revenue Growth
+26.35%
P/S Ratio
n/a
Revenue / Employee
$297.57K
Employees
91
Market Cap
189.63M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Genus | 668.80M |
Aclaris Therapeutics News
- 11 days ago - New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewsWire
- 12 days ago - Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule - Seeking Alpha
- 23 days ago - Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 2 months ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 2 months ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire